Five Prime Signs US$530 M Licensing Deal with Seattle Genetics
By Michelle Liu
Pharma Deals Review: Vol 2020 Issue 2 (Table of Contents)
Published: 25 Feb-2020
DOI: 10.3833/pdr.v2020.i2.2515 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Building its antibody-drug conjugate portfolio, Seattle Genetics has agreed to in-license a family of monoclonal antibodies directed to a single target from Five Prime Therapeutics in exchange for US$5 M upfront...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS